Cidara Therapeutics, Inc.
Symbol: CDTX (NASDAQ)
70.54
▲ (2.66%) 1.830
Company Description:
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Key Stats
- Today's Open: $70.72
- Today's High: $72.18
- Today's Low: $68.1
- Today's Volume: 179.03K
- Yesterday Close: $68.71
- Yesterday High: $74.515
- Yesterday Low: $68.48
- Yesterday Volume: 1.83M
- Last Min Volume: 294
- Last Min High: $70.552
- Last Min Low: $70.54
- Last Min VWAP: $70.54069
Company Profile
- Name: Cidara Therapeutics, Inc.
- Website: https://www.cidara.com
- Listed Date: 2015-04-15
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001610618
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $1.74B
- Round Lot: 100
- Outstanding Shares: 25.36M
- Asset Type: CS
RECENT FILINGS FOR CDTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-15 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-08-11 | SCHEDULE 13D/A | View |
| 2025-08-07 | S-8 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-30 | SCHEDULE 13G | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-07-02 | SCHEDULE 13G | View |
| 2025-06-30 | SCHEDULE 13D/A | View |
| 2025-06-30 | 4 | View |
| 2025-06-25 | 8-K | View |
| 2025-06-25 | 424B5 | View |
| 2025-06-24 | 8-K | View |
| 2025-06-23 | 424B5 | View |
Latest News on CDTX